Side by side
Consultation participation and their own register declarations, side by side. Counts, not judgments — participation is not influence.
Counts here are a floor, never a total: they cover the 583 consultation files tracked so far (42,224 submissions, mostly 2025–26), so an organization's real filing history is larger, not smaller.
Other · Switzerland
NGO · Belgium
Declared costs: not declared · in the register since 2010
Medicinal products for human use · A European Health Data Space · Revision of the EU legislation on medicines for children and rare diseases
Register facts self-declared (snapshot 2 Sept 2026); cost bands are floors. Shared files are shared attention, not evidence of coordination.
Their opening passages on the files they share, verbatim and in filing order. We do not summarize, compare, or characterize positions — read them at source.
Rare Cancers Europe · filed 27 Apr 2021 · source
Rare Cancers Europe (RCE), a 40-partner strong multi-stakeholder partnership, welcomes the consultation and would like to emphasise the following: 1. Ensure access: • HTA: RCE encourages the harmonisation of HTA processes and to ensure the concept of joint clinical assessments, to avoid the duplication of clinical assessments at national level, as foreseen by the draft HTA regulation.
European Public Health Alliance (EPHA) · filed 27 Apr 2021 · source
The revision of the EU general pharmaceuticals legislation should aim to address the problems of availability, accessibility and affordability of medicines as well as to incentivise meaningful, public health needs-driven biomedical innovation. Put simply, it should serve the goal of having better and affordable medicines for those who need them.
Rare Cancers Europe · filed 3 Feb 2021 · source
Rare Cancers Europe (RCE), a 40-partner strong multi-stakeholder partnership, welcomes the EU efforts towards the creation of a European Health Data Space (EHDS). Rare cancers are a neglected area deserving dedicated attention as 24% of all new cancer diagnoses, including all paediatric cancers, are rare.
European Public Health Alliance (EPHA) · filed 3 Feb 2021 · source
EPHA welcomes the European Health Data Space as a Commission priority and is pleased that it is seen as a way to increase the ability of digital health to reduce inequalities and provide high-quality healthcare.
European Public Health Alliance (EPHA) · filed 18 Dec 2020 · source
Small biotechs, university spin-offs and other research institutions are now at the heart of pharmaceutical R&D conducting the early-stage research, financed by venture capitalists, hedge funds and private equity. Large pharmaceutical companies perform less research in-house while they scan the horizon for promising products and companies. They subsequently acquire them.
Rare Cancers Europe · filed 6 Jan 2021 · source
Rare Cancers Europe (RCE), a 39 partner strong multi-stakeholder partnership, welcomes the EU efforts to assessing solutions to improve the legislative environment on medicines for rare diseases, including rare cancers. With more than 20% of all new cancer cases being rare, including all paediatric cancers, rare cancers belong to both cancers and rare diseases.
2 organizations on one sheet: every file each filed on, their register declarations, and a working link to each submission. Free: we ask for your name and email, and PolicySpeak may contact you about the product (privacy policy). The per-file record stays downloadable without signing up on each file’s page.